KYTX
USDKyverna Therapeutics Inc. Common Stock
Цена в режиме реального времени
График цен
Ключевые показатели
Рыночные показатели
Открытие
$6.670
Максимум
$6.930
Минимум
$6.670
Объем
0.31M
Фундаментальные показатели компании
Рыночная капитализация
291.5M
Отрасль
Биотехнология
Страна
United States
Статистические данные торговли
Средний объем
0.57M
Биржа
NMS
Валюта
USD
52-недельный диапазон
Связанные новости
FDA's Rigid Approach Adds Uncertainty To uniQure's Accelerated Pathway For Huntington's Gene Therapy
William Blair notes FDA's tougher stance on gene therapy programs as AMT-130 faces uncertainty in its accelerated approval timeline.
Wells Fargo Maintains Overweight on Kyverna Therapeutics, Raises Price Target to $31
Wells Fargo analyst Derek Archila maintains Kyverna Therapeutics with a Overweight and raises the price target from $27 to $31.
Kyverna Therapeutics Announces Positive Interim Phase 2 Data from KYSA-6 Study of KYV-101 in Generalized Myasthenia Gravis at AANEM 2025
Compelling results set new clinical standard in generalized myasthenia gravis (gMG), increasing confidence in the Company's registrational KYSA-6 Phase 3 MG trial 100% of patients achieved clinically meaningful
HC Wainwright & Co. Maintains Buy on Kyverna Therapeutics, Raises Price Target to $20
HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Kyverna Therapeutics with a Buy and raises the price target from $10 to $20.
Kyverna Therapeutics Highlights Potential of KYV-101 in Rheumatoid Arthritis with Phase 1 Data from Investigator-Initiated Trial Presented at ACR Convergence 2025
KYV-101 resulted in a profound reduction in disease-associated autoantibodies and impact on disease activity in patients with difficult-to-treat rheumatoid arthritis (RA) KYV-101 continues to demonstrate a
Kyverna Therapeutics to Host Conference Call on Interim Phase 2 Data from KYSA-6 Study of KYV-101 in Generalized Myasthenia Gravis
EMERYVILLE, Calif., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (NASDAQ:KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases,
Связанные акции
Оставаться в курсе
Установите ценовой сигнал, получите обновления анализа ИИ и новости рынка в режиме реального времени.